In vitro activity of quinupristin/dalfopristin (Synercid, RP 59500) against Legionella spp

Diagn Microbiol Infect Dis. 2000 Jan;36(1):49-52. doi: 10.1016/s0732-8893(99)00107-8.

Abstract

The activities of quinupristin/dalfopristin (Synercid), erythromycin and azithromycin against 22 Legionella spp. isolates were measured by a microbroth dilution method. The MICs that inhibited 90% of strains tested were 0.5, 0.35, and 0.5 microg/mL for quinupristin/dalfopristin, erythromycin, and azithromycin, respectively. Quinupristin/dalfopristin was only partially active against intracellular L. pneumophila at high (2 microg/mL), but not low (1 microg/mL) concentration. Activity of the drug in a guinea pig model of Legionnaires' disease could not be accurately determined because of drug toxicity for the guinea pig, although there was evidence that the drug has in vivo activity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Confidence Intervals
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination / pharmacology*
  • Guinea Pigs
  • Humans
  • Injections, Intraperitoneal
  • Legionella / classification
  • Legionella / drug effects*
  • Legionellosis / drug therapy*
  • Microbial Sensitivity Tests
  • Reference Values
  • Sensitivity and Specificity
  • Virginiamycin / pharmacology*

Substances

  • Virginiamycin
  • quinupristin-dalfopristin